Podcast

Speaking Out About Breast Implant-Associated Cancer

Author(s):

Kristie L. Kahl

In this episode of CURE® Talks Cancer, we spoke with an advocate who is raising awareness around the recent controversy surrounding a certain type of breast implant that is causing a rare type of lymphoma.

Imagine overcoming a breast cancer diagnosis and its treatment, yet in choosing reconstructive surgery with textured implants, finding out you may be at risk for a rare type of lymphoma.

Renee Ridgeley found herself in that exact situation.

Following the recent controversy with a Food and Drug Administration panel not banning these implants that are to blame for causing breast implant-associated anaplastic large-cell lymphoma, many women are speaking out about the issue.

In this week’s CURE® Talks Cancer podcast, we spoke with the patient advocate about her own experience and how women can learn more about their reconstruction options.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Picture of Dr. Pouneh Razavi
Related Content
Image of Patti.
June 12th 2025

Beyond Treatment: How Support Groups Helped Me Embrace My New Normal

Patti McGee
Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Dr. Mabel Mardones educates patients on breast cancer updates: © stock.adobe.com.
June 10th 2025

Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions

Kristie L. Kahl
Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
The ADC zilovertamab vedotin plus Rituxan and chemo showed an ORR of 56.3% in relapsed/refractory DLBCL: © stock.adobe.com.
June 9th 2025

Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL

Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for R/R nodal T-follicular helper cell lymphoma: © stock.adobe.com.
June 9th 2025

TERZO Trial Doses First Patient With Copiktra in Rare T-Cell Lymphoma

Spencer Feldman
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.